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Hexahydro-1,3,5-trinitro-1,3,5-triazine 
(RDX; royal demolition explosive) is a high-
energy cyclic compound developed before 
World War II and has a history of worldwide 
use in explosive mixtures and formulations, 
such as C-4 (McLellan et al. 1992; Yinon 
1990). RDX can be released into the environ-
ment by way of waste streams generated dur-
ing the manufacture, use, and disposal of the 
pure product or RDX-containing munitions 
(McLellan et al. 1992). Another possible 
route of exposure is unexploded munitions 
found on training ranges, with the accompa-
nying risk of ground  water leaching [Agency 
for Toxic Substances and Disease Registry 
(ATSDR) 2010]. The risk of inadvertent 
release to ground  water or soil has resulted in 
U.S. Environmental Protection Agency (EPA) 
regulations governing human oral exposure. 
Based on more recent studies (Crouse et al. 
2006; Gust et al. 2009; Kasuske et al. 2009; 
Kucukardali et al. 2003), the U.S. EPA is cur-
rently reassessing RDX information available 
in the Integrated Risk Information System 
database (U.S. EPA 1993). 
For > 60 years it has been known that 
human exposure to high doses of RDX causes 
headache, dizziness, vomiting, and confusion, 
followed by tonic-clonic seizures (Barsotti and 
Crofti 1949; Kasuske et al. 2009; Kucukardali 
et al. 2003). Although initial isolated reports 
were of accidental exposure during manu-
facture or other contamination (ATSDR 
2010; U.S. EPA 1993), case reports peaked 
during the Vietnam War, when RDX was 
inadvertently ingested by soldiers using it to 
ignite cooking fires, or intentionally taken 
as an illicit intoxicant (Stone et al. 1969); 
such case reports still appear (Kasuske et al. 
2009). Intense seizures and status epilepti-
cus after experimental RDX exposure have 
also been observed in a wide range of species, 
from lizards and birds to non    human primates 
(Burdette et al. 1988; Crouse et al. 2006; 
Gust et al. 2009; Martin and Hart 1974; 
Quinn et al. 2009; Schneider et al. 1977; Von 
Oettingen et al. 1949). It has been speculated 
that the limbic plays a primary role in RDX-
induced seizures (Burdette et al. 1988), but 
the cellular mechanism of seizure induction 
has been unknown. Here, we present evidence 
that RDX binds at the convulsant site of the 
γ-aminobutyric acid type A (GABAA) recep-
tor (Benarroch 2007; Johnston 2005; Kalueff 
2007), causing reduction of GABAA receptor–
mediated synaptic transmission and induction 
of epileptiform activity, as we demon  strate in 
the amygdala, a seizure-prone structure of the 
limbic system (Aroniadou-Anderjaska et al. 
2007, 2008).
Materials and Methods
RDX.  We  obtained  RDX  from  the 
Department of the Navy (Naval Ordnance and 
Security Activity, Indian Head, MD); HPLC 
analy  sis showed it to be > 99.5% pure, with 
the remainder being water. For animal experi-
ments, RDX was dissolved in 1% methyl-
cellulose and 0.2% Tween-80 and adminis  tered 
to rats by oral gavage at the dose of 75 mg/kg, 
a dose that consistently induces seizures within 
30 min after adminis  tration (McCain W, 
personal communication). Control rats 
received a vehicle solution that consisted of 
1% methyl  cellulose and 0.2% Tween-80 
without RDX; vehicle was also adminis-
tered by oral gavage. For in vitro studies,   
RDX was dissolved in dimethyl sulfoxide 
(DMSO) at a 100× concentration to minimize 
the percentage of DMSO in the final dilution.
In vivo electrophysiological experiments. 
Male Sprague-Dawley rats were individu-
ally housed in an environmentally controlled 
room (20–23°C; 12-hr light/dark cycle, 
with lights on 0600 hours), with food and 
water available ad libitum. The rats weighed 
150–250 g at the beginning of the experi-
ments. All animal experiments were approved 
by the Institutional Animal Care and Use 
Committee of the U.S. Army Center for 
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Ba c k g r o u n d: Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) is a high-energy, tri    nitrated cyclic 
compound that has been used worldwide since World War II as an explosive in both military and 
civilian applications. RDX can be released in the environment by way of waste streams gener-
ated during the manufacture, use, and disposal of RDX-containing munitions and can leach into 
ground  water from unexploded munitions found on training ranges. For > 60 years, it has been 
known that exposure to high doses of RDX causes generalized seizures, but the mechanism has 
remained unknown.
oB j e c t i v e: We investigated the mechanism by which RDX induces seizures.
Me t h o d s  a n d r e s u l t s: By screening the affinity of RDX for a number of neurotransmitter recep-
tors, we found that RDX binds exclusively to the picrotoxin convulsant site of the γ-aminobutyric 
acid type A (GABAA) ionophore. Whole-cell in vitro recordings in the rat basolateral amygdala (BLA) 
showed that RDX reduces the frequency and amplitude of spontaneous GABAA receptor–mediated 
inhibitory postsynaptic currents and the amplitude of GABA-evoked post  synaptic currents. In extra-
cellular field recordings from the BLA, RDX induced prolonged, seizure-like neuronal discharges. 
co n c l u s i o n s: These results suggest that binding to the GABAA receptor convulsant site is the 
primary mechanism of seizure induction by RDX and that reduction of GABAergic inhibitory 
transmission in the amygdala is involved in the generation of RDX-induced seizures. Knowledge 
of the molecular site and the mechanism of RDX action with respect to seizure induction can guide 
therapeutic strategies, allow more accurate development of safe thresholds for exposures, and help 
prevent the development of new explosives or other munitions that could pose similar health risks.
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Health Maintenance and Preventive Medicine 
and the Uniformed Services University of the 
Health Sciences. The investigators adhered to 
the Guide for the Care and Use of Laboratory 
Animals (Institute of Laboratory Animal 
Resources 1996), which requires humane 
treatment of all animals, with regard for alle-
viation of suffering.
Rats were anesthetized with a combina-
tion of ketamine [80 mg/kg, intraperi  toneally 
(IP)] and xylazine (10 mg/kg, IP), and cor-
tical stainless steel electrodes (Plastics One, 
Roanoke, VA) were stereo  taxically implanted 
over the left and right frontal cortex (2.0 mm 
posterior and 2.5 mm lateral to bregma) and 
left and right parietal cortex (5.5 mm poste-
rior and 2.5 mm lateral to bregma), with a 
reference electrode implanted over the cer-
ebellum (1.5 mm posterior from lambda). 
After 1 week of recovery, rats were placed in 
the electro  encephalogram (EEG) chamber 
and connected to the EEG system (Stellate, 
Montreal, Canada). Video-EEG recordings 
of baseline activity in the freely moving rats 
began at least 10 min before oral dosing of 
RDX. Both the control and RDX-dosed rats 
were monitored for up to 3 hr after dosing.
Measurements of in vivo acetylcholin-
esterase (AChE) and RDX concentrations. 
Rats were administered vehicle or RDX as 
described above. At the time of seizure onset, 
the rats were euthanized and samples of frontal 
lobe and blood were taken for measurements 
of AChE activity and content of RDX. We 
determined AChE activity in frontal cortex 
homogenates using the 96-well microplate 
method of Padilla et al. (1998). A 2% (wet 
wt/vol) homogenate was made in 0.1 M 
Na-phosphate buffer (pH 8.0) plus 1% Triton, 
using a 20-sec burst (on ice) of a Polytron AJ 
10/35 (Brinkman Instruments, Rexdale, 
Ontario, Canada). Total cholinesterase [brain 
cholinesterase is 95% AChE (Padilla et al. 
1998)] was determined at 37°C by meas  uring 
the change in absorbance at 412 nm over 5 in 
in a 96-well plate reader (Bio-Tek Synergy HT, 
Winooski, VT) using acetylcholine iodide as 
substrate and 5,5´-dithio-bis[2-nitrobenzoic 
acid] as the colori  metric indicator. We gener-
ated a glutathione sulfhydryl standard curve 
for conversion of absorbance units into nano-
moles of sulfydryl groups. AChE enzymatic 
activity in the brain samples was then calcu-
lated as micromoles of substrate hydrolyzed 
per minute per gram wet weight (ww) (Padilla 
et al. 1998). Blood and brain samples were 
assayed for RDX content by the U.S. Army 
Public Health Command Directorate of 
Laboratory Sciences using gas chromatography 
with electron capture detection (GC-ECD) 
(Bishop et al. 2003).
Receptor binding assays. Neurotransmitter 
receptor binding assays for RDX were per-
formed by Ricerca Biosciences (Concord, 
OH). The specific assays and catalog numbers 
are listed in Table 1. Initially, RDX was tested 
at a single concentration of 33 µM. Routine 
screening for receptor affinity is usually done 
with a compound concentration of 10 µM 
(Ricerca Biosciences). To better ensure the 
probability of a “hit” with RDX, the initial 
test of RDX was performed using 33 µM, a 
half-log higher concentration. Subsequently, 
a complete dose response of RDX was tested 
in the [35S]-t-butyl  bicyclo  phospho  orothionate 
([35S]-TBPS) convulsant site assay (catalog 
no. 226830) using picro  toxin as standard; 
this assay is based on the method of Maksay 
(1993). The maximal inhibitory concentra-
tions (IC50) were determined by a non  linear 
least-squares regression analysis using MathIQ 
(ID Business Solutions Ltd., Guildford, Surrey, 
UK). The inhibition constant (Ki) values were 
calculated using the equation of Cheng and 
Prusoff (1973), the observed IC50 of the tested 
compound, the concentration of radioligand 
employed in the assay, and the historical val-
ues for the dissociation constant (KD) of the 
ligand (obtained experimentally at Ricerca 
Biosciences).
In vitro extracellular and whole-cell 
patch-clamp recordings. Acute amygdala 
slices were prepared from male Sprague-
Dawley rats (200–250 g body weight) as 
described previously (Aroniadou-Anderjaska 
et al. 2001; Braga et al. 2003). The arti-
ficial cerebro  spinal fluid (ACSF) consisted 
of 125 mM NaCl, 2.5 mM KCl, 2.0 mM 
CaCl2, 1.0 mM MgCl2, 25 mM NaHCO3, 
1.25 mM NaH2PO4, and 11 mM glucose, 
bubbled with 95% O2/5%CO2 to maintain 
a pH of 7.4. For extra  cellular field poten-
tial recordings, slices were transferred to an 
interface-type recording chamber maintained 
at 32°C, where they were perfused with ACSF 
at 0.7–1 mL/min. Spontaneous activity was 
recorded in the basolateral amygdala (BLA) 
in the gap-free mode (continuous recordings), 
while evoked field potentials were sampled 
by delivering single stimulation pulses to the 
external capsule at 30-sec intervals. Recording 
glass pipettes were filled with ACSF and had 
a resistance of approximately 5 MΩ. Bipolar 
stimulating electrodes were constructed 
from twisted stainless steel wire, 50 µm in 
diameter. Spontaneous and evoked analog 
signals were digitized using pClamp10 soft-
ware (Molecular Devices, Division of MDS 
Analytical Technologies, Sunnyvale, CA).
For whole-cell recordings, slices were 
transferred to a submersion-type recording 
chamber (0.7 mL volume), where they were 
continuously perfused with oxygenated ACSF 
at a rate of 3–5 mL/min. The techniques 
employed were similar to those described 
previously (Braga et al. 2003; Pidoplichko 
and Dani 2005). All experiments were per-
formed at 32–33°C. We visualized neurons 
under infrared light using Nomarski optics 
of an upright microscope (Zeiss Axioskop 2; 
Carl Zeiss MicroImaging, Thornwood, NY) 
equipped with a CCD-100 camera (Dage-
MTI, Michigan City, IN). Tight-seal (> 1 
GΩ) whole-cell recordings were obtained 
from the cell body of pyramidal-shaped neu-
rons in the BLA region. Access resistance 
(5–24 MΩ) was regularly monitored dur-
ing recordings, and cells were rejected if the 
resistance changed by > 15% during the 
experiment. Patch electrodes were fabricated 
from borosilicate glass and had a resistance 
from 3 to 4 MΩ when filled with solution 
A (60 mM CsCH3SO3, 60 mM KCH3SO3, 
10 mM KCl, 10 mM EGTA, 10 mM 
HEPES, 5 mM Mg-ATP, 0.3 mM NaGTP, 
pH 7.2; 280–290 mOsm/kg) or with solution 
B (135 mM Cs-gluconate, 10 mM MgCl2, 
0.1 mM CaCl2, 1 mM EGTA, 10 mM 
HEPES, 2 mM Na-ATP, 0.2 mM Na3GTP, 
pH 7.2; 280–290 mOsm/kg). Solution B 
(high Cs+) stabilizes cell leakage (allowing 
prolonged periods of recording) but depresses 
the hyperpolarization-activated current (Ih), 
whereas solution A (lower Cs+) still keeps the 
leakage low without affecting the Ih current. 
Neurons were voltage-clamped at +40 mV 
(intra  pipette solution A) or at –70 mV (intra-
pipette solution B) holding potential, using an 
Axopatch 200B amplifier (Axon Instruments, 
Foster City, CA).
We performed pressure application 
of GABA with the help of the push–pull 
  experi  mental arrangement (Pidoplichko and 
Table 1. List of binding assays screened for affin-
ity of RDX.
Catalog 
no. Receptor/binding site
Percent 
inhibition
235010 Glutamate, nonspecific 7
232600 Glutamate, AMPA –10
233000 Glutamate, NMDA, phencyclidine 2
258590 Nicotinic acetylcholine 9
254000 Muscarinic, nonselective, central 7
239000 Glycine, strychnine sensitive 2
279510 Sodium channel, site 2 16
228510 GABA, nonselective 4
226810 GABAA, chloride channel, TBOB 76a
226830 GABAA, chloride channel, TBPS 78a
226600 GABAA, flunitrazepam, central 5
226500 GABAA, muscimol, central 13
203500 Adrenergic α1, nonselective –11
203900 Adrenergic α2, nonselective –5
260500 Opiate, nonselective 7
226700 Peripheral benzodiazepine receptor –6
268700 Purinergic P2X 10
271000 Serotonin 5-HT1, nonselective 26
271200 Serotonin 5-HT1B –5
271910 Serotonin 5-HT3 –9
272000 Serotonin 5-HT4 12
279510 Sodium channel, site 2 –5
220320 Transporter, dopamine (DAT) 0
204410 Transporter, norepinephrine –6
274030 Transporter, serotonin (SERT) –5
Catalog numbers are from Ricerca Biosciences.
aMet criteria for significance.RDX blocks GABA currents
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Dani 2005). Pressure was applied to the pipette 
via a Picospritzer (General Valve Division, 
Parker Hannifin Corp., Fairfield, NJ), set at 
about 225 Pa (30 psi). A motorizer (Newport, 
Fountain Valley, CA) was coupled with the 
approach/withdrawal (push–pull) actuator of a 
micro  manipulator (Burleigh PCS-5000 series; 
EXFO Photonic Solution Inc., Mississauga, 
Ontario, Canada). Motorizer movement and 
duration of application pulses were controlled 
with a Master-8 digital stimulator (AMPI; 
Jerusalem, Israel). Ionic currents were amplified 
and filtered (1 kHz) using an Axopatch 200B 
amplifier, with a four-pole low-pass Bessel fil-
ter, and were digitally sampled (up to 5 kHz). 
Currents were recorded using pClamp10 soft-
ware (Axon Instruments) and further analyzed 
using OriginLab (Northampton, MA) and 
Mini60 software (Synaptosoft, Fort Lee, NJ). 
We used the following receptor/channel   
antagonists during whole-cell recordings:   
6-cyano-7-nitroquinoxaline-2,3-dione 
(CNQX), an α-amino-3-hydroxyl-5-methyl-
4-isoxazole-propionate (AMPA)/kainate recep-
tor antagonist; d-2-amino-phosphonovalerate 
(AP-5), an N-methyl-d-aspartic acid (NMDA) 
receptor antagonist; and SCH50911, a GABAB 
receptor antagonist, all from Tocris Cookson 
(Ballwin, MO). We also used bicuculline 
methiodide, a GABAA receptor antagonist, and 
tetrodotoxin, a sodium channel blocker, both 
from Sigma Chemical Co. (St. Louis, MO). 
Statistical analysis. Statistical significance 
was determined using unpaired or paired 
Student’s t-test. Differences were considered 
statistically significant when the probability 
for error was < 0.05. Data are presented as 
mean ± SE. 
Results
RDX administration induces seizure activity 
in vivo. We characterized RDX-induced sei-
zures in vivo using behavioral observations and 
EEG recordings from surface-implanted elec-
trodes. Rats (n = 4) were administered RDX 
(75 mg/kg) via oral gavage and allowed to move 
freely in their cages. Eleven to 16 min after 
RDX administration, rats presented one or 
more myoclonic twitches, followed by a single 
tonic-clonic seizure. The myoclonic twitch was 
accompanied, in the EEG, by a single sharp 
wave. We observed rhythmic, continuous, and 
high-amplitude poly  spikes in the EEG during 
tonic-clonic seizures (Figure 1). This pattern of 
myo  clonic twitches preceding a tonic-clonic sei-
zure continued such that each rat had three or 
four tonic-clonic seizures within the next 1.5 hr 
before an episode of wild running/jumping.   
After the running/jumping, a final lasting 
tonic-clonic seizure with loss of righting reflex 
continued until death at 2–3 hr after RDX 
adminis  tration. Control rats that received only 
vehicle solution displayed normal behavior and 
normal electrographic activity.
Effects  of  RDX  on  brain  AChE. 
Organophosphorus pesticides and nerve agents 
are potent inhibitors of peripheral and cen-
tral nervous system AChE. Exposure to these 
agents causes excessive salivation and lacrima-
tion in addition to seizure induction (Shih 
et al. 2003). Because of anecdotal reports of 
increased salivation and/or lacrimation associ-
ated with RDX intoxication (Burdette et al. 
1988; Crouse et al. 2006; Schneider et al. 
1977), we specu  lated that RDX-induced sei-
zures might involve a similar inhibition of 
brain AChE. To examine this possibility, we 
administered RDX (75 mg/kg) or vehicle solu-
tion to rats (n = 6/group). Seizures appeared 
10–21 min after dosing, but we did not 
observe increased salivation or lacrimation. At 
the onset of seizures, the rats were euthanized, 
and samples of the frontal lobe and blood were 
collected for measure  ments of AChE activity 
and content of RDX. AChE activity in the 
vehicle- and RDX-treated groups was identi-
cal (6.6 ± 0.4 µmol/min/g ww). Thus, seizure 
induction by RDX does not involve inhibition 
of AChE.
Blood and brain concentrations of RDX 
during seizures. Analysis of the blood and 
frontal cortex samples taken at the onset of 
RDX-induced seizures indicated a direct cor-
relation of blood to brain concentrations 
of RDX (Figure 2A); the correlation coef-
ficient (CC) was 0.81. This result indicates 
that RDX readily enters the brain in direct 
proportion to the level of RDX in the blood 
after intestinal absorption. The correlation of 
brain RDX concentration with time to seizure 
onset after the oral gavage dose is presented in 
Figure 2B (CC = –0.61). These data indicate 
that the higher the brain concentration of 
RDX, the shorter the time interval between 
RDX administration and seizure onset.
RDX binds to the convulsant site of the 
GABAA receptor. To determine the binding 
sites of RDX in the brain that may be involved 
in seizure induction, we screened a battery 
of neuro  transmitter receptors for affinity to 
RDX. The receptors assayed included those 
implicated as targets of known convulsants, 
such as the glutamate family of receptors, nic-
otinic and muscarinic acetylcholine receptors, 
the glycine receptor, the family of GABAA 
receptor ligand sites, the batrachotoxin site 
of the sodium channel (site 2) (Catterall et al. 
1981), and several others (Table 1). Out of 
this comprehensive list, the only binding site 
for which RDX had significant affinity was the 
TBPS/picrotoxin/t-butylbicyclo  ortho  benzoate 
(TBOB) convulsant site of the GABAA recep-
tor (Kalueff 2007; Maksay 1993). RDX 
inhibited [35S]-TBPS and [35S]-TBOB bind-
ing by > 70% at the screening RDX con-
centration of 33 µM. In Figure 3, the full 
dose–response [35S]-TBPS binding curve is 
shown for both RDX and picro  toxin, which 
Figure 1. In vivo administration of RDX caused generalized electrographic seizures in rats. (A) Baseline 
EEG recording before RDX administration. (B) Representative EEG activity showing a generalized seizure, 
1 hr after RDX administration (75 mg/kg, by gavage). Traces in A and B were recorded (top to bottom) from 
a left frontal (1), right frontal (2), left parietal (3), and right parietal (4) cortical screw electrode, as shown in 
the diagram. 
Baseline
1 mV
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1
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Figure 2. Bioavailability of RDX at the time of RDX-induced seizure onset. (A) Correlation between blood 
and brain RDX concentrations at seizure onset (CC = 0.81). (B) Correlation between RDX brain concentra-
tion and time to seizure onset; the negative correlation (CC = –0.61) indicates that the higher the brain 
concentration of RDX, the shorter the time to seizure initiation. 
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was used as a positive control; RDX has an 
apparent Ki of 21.1 ± 2.1 µM, compared 
with picrotoxin, which has an apparent Ki of 
0.20 ± 0.042 µM.
RDX reduces GABAA currents and induces 
seizure-like activity in the BLA in vitro. Having 
found that RDX binds to the convulsant site 
of the GABAA receptor, we next examined 
the functional consequences by determin-
ing the effect of RDX on GABAA receptor– 
mediated currents in the baso  lateral nucleus 
of the amygdala (BLA). The amygdala plays a 
central role in seizure generation, with the BLA 
being the most important nucleus involved in 
this role (Aroniadou-Anderjaska et al. 2007, 
2008; Mohapel et al. 1996; White and Price 
1993), and previous studies have suggested that 
the amygdala is a target for RDX (Burdette 
et al. 1988; Levine et al. 1990; Macphail et al. 
1985). In in vitro brain slices, we identified 
recorded neurons in the BLA as principal cells 
on the basis of their pyramidal shape and the 
presence of a current activated by hyperpolari-
za  tion (Ih current). About 85% of amygdala 
neurons are principal pyramidal neurons dis-
playing Ih (Park et al. 2007). We detected the 
presence of Ih by applying hyper  polarizing 
steps from the holding potential of –70 mV 
with 10-mV increments.
First, we examined the effects of RDX 
on action-potential–dependent spontaneous 
inhibitory post  synaptic currents (sIPSCs) 
recorded at holding potential (Vh) = +40 mV 
(Figure 4A) with intra  cellular/recording   
pipette solution A (see “Materials and 
Methods”) or at Vh = –70 mV (Figure 4B) 
with intra  cellular solution B, in the pres-
ence of CNQX (10 µM), AP-5 (50 µM), and 
SCH50911 (20 µM) to block AMPA/kainate, 
NMDA, and GABAB receptors, respectively. 
Bath application of 30 µM RDX significantly 
reduced both the frequency and amplitude 
of the sIPSCs, from 21 ± 3 events/sec and 
60 ± 10 pA (n = 4) in control conditions to 
8 ± 2 events/sec and 31 ± 4 pA in the pres-
ence of RDX (n = 4, p < 0.05). Examples are 
shown in Figure 4A and B, and the group 
results are shown in Figure 4C and D. sIPSCs 
recovered only partially after 12-to 15-min 
wash  out of RDX. The recovered currents were 
completely blocked by the GABAA receptor 
antagonist bicuculline (20 µM; Figure 4B).
To directly demonstrate the blockade of 
GABA currents by RDX, we examined the 
effect of RDX on the currents induced by 
local pressure application of GABA. Pressure-
applied GABA (200 µM) for 500 msec to 
pyramidal-shaped BLA neurons, in the pres-
ence of CNQX (10 µM), AP-5 (50 µM), 
and SCH50911 (20 µM), elicited currents 
that were significantly reduced by 40 µM 
RDX added to the bath (37 ± 3% reduction, 
mean ± SE; n = 6; Figure 5). Current ampli-
tudes recovered only partially after the wash-
out of RDX.
To determine the impact of the reduction 
of sIPSCs by RDX on the overall activity of 
the BLA neuronal network, we applied RDX 
(100 µM) to the slice medium while recording 
extra  cellular field spontaneous activity. RDX 
induced prolonged, seizure-like neuronal dis-
charges in the BLA within 15–25 min after 
exposure (n = 4; Figure 6). We applied single- 
pulse stimuli every 30 sec to sample the 
evoked field potential responses. Seizure-like 
activity was triggered by each stimulus pulse 
but was also present when stimu  lation was 
Figure 3. Dose–response curve for RDX and picro-
toxin on [35S]-TBPS binding. The assays were per-
formed in triplicate using a standard binding assay 
with rat brain membranes (Maksay 1993). The cal-
culated Ki for RDX is 21.1 ± 2.1 µM. 
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Figure 4. RDX reduced the frequency and amplitude of GABAA receptor–mediated sIPSCs in the BLA; 
whole-cell recordings from principal neurons in the BLA were obtained in the presence of CNQX, AP-5, 
and SCH50911. (A) sIPSCs recorded at Vh = +40 mV. The outward currents were reduced in both frequency 
and amplitude by bath application of 30 µM RDX (black bar over the current trace) and recovered partially 
after 12-min wash  out of RDX. The recovered currents were completely blocked by the GABAA receptor 
antagonist bicuculline (20 µM; data not shown). (B) sIPSCs recorded at Vh = –70 mV. Bath-applied RDX 
(30 µM) reduced both the frequency and the amplitude of the inward currents. After 12-min wash  out of 
RDX, sIPSCs recovered only partially. Bath-applied bicuculline (20 µM) blocked the spontaneous currents. 
The lower row illustrates example current traces at an expanded time scale from control recording (one 
asterisk), in RDX (two asterisks), and after wash  out of RDX (three asterisks). (C) Decrease in the frequency 
of high-amplitude events (the threshold was set at 20 pA) by RDX. (D) Decrease in amplitude of sIPSCs in 
the presence of RDX (bin width, 10 pA; n = 4 slices/cells). 
#p < 0.05 by paired t-test. 
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turned off (Figure 6B,C). The effect of RDX 
was not reversible at least after 40 min of 
RDX washout. 
Discussion
RDX has been used extensively as an explosive 
in both military and civilian applications. The 
health hazards from RDX exposure have been 
known since the 1940s, with brain seizures and 
status epilepticus as one of the major symp-
toms of RDX intoxication seen in humans 
(Barsotti and Crofti 1949; Stone et al. 1969) 
and rats (Burdette et al. 1988; Macphail et al. 
1985; Schneider et al. 1978; Von Oettingen 
et al. 1949). However, until the present day 
there has been no information regarding the 
mechanisms by which RDX induces seizures. 
The major finding of the present study is that 
RDX binds to the picrotoxin convulsant site 
of the GABAA receptor and inhibits GABAA 
receptor–mediated synaptic transmission; 
this is likely to be the primary mechanism by 
which RDX induces brain seizures.
RDX-induced seizures. Previous reports 
have described seizures in humans after acci-
dental acute consumption of RDX (Hollander 
and Colbach 1969; Kasuske et al. 2009; Stone 
et al. 1969; Woody et al. 1986). Animal stud-
ies have also demon  strated the induction of 
seizures after RDX administration (Burdette 
et al. 1988; Crouse et al. 2006; Gust et al. 
2009; Macphail et al. 1985; Martin and Hart 
1974; Schneider et al. 1977; Von Oettingen 
et al. 1949). Because RDX causes rats to con-
vulse within seconds after intravenous injec-
tion, Schneider et al. (1977) concluded that 
convulsions are caused by the parent com-
pound rather than a neurotoxic metabolite 
of RDX. The present study supports this 
view because the brain concentration of 
RDX correlated positively with the time to 
seizure initiation and because RDX reduced 
GABAergic transmission and induced epilepti-
form activity in isolated brain slices. In addi-
tion, the present findings indicate that RDX 
is rapidly absorbed after oral adminis  tration 
and readily crosses the blood–brain barrier. A 
brain level of 8 µg/g ww was the lowest level 
we observed in the RDX-treated rats at the 
time of seizure onset, implying that this brain 
level is adequate for seizure initiation. The 
variability in blood/brain RDX concentra-
tions among animals is probably related to 
differential absorption of the water-insoluble 
RDX in the methyl  cellulose suspension.
Burdette et al. (1988) suggested that the 
limbic system is significantly involved in 
RDX-induced seizures, based on the observa-
tion that amygdala kindling was accelerated 
in rats that received a relatively low daily dose 
of RDX. Here, we show that RDX reduces 
GABAA receptor–mediated inhibitory synaptic 
transmission in the rat BLA, producing hyper-
excitability and the appearance of seizure-like 
neuronal discharges in vitro. Consistent with 
the view that the amygdala is a primary tar-
get of RDX, and the well-known role of the 
amygdala in startle responses (Davis et al. 2008) 
and aggressive behavior (Mpakopoulou et al. 
2008), rats that are adminis  tered RDX and do 
not reach the threshold for seizures display an 
increased acoustic startle response (Macphail 
et al. 1985), as well as an overall hyper  reactivity 
and increased fighting (Levine et al. 1990).
Mechanisms of RDX seizure induction. 
Many convulsants induce seizures by reducing 
GABAergic inhibition, either by competitively 
antagonizing GABA or by directly blocking 
chloride influx through the GABAA chan-
nel (Kalueff 2007; Rowlett et al. 2005). The 
“cage convulsants,” compounds with cyclical 
structure, bind at a convulsant binding pocket 
inside the GABAA ionophore at different—and 
possibly overlapping—positions. This “binding 
pocket” of the GABAA channel is also referred 
to as the picro  toxin convulsant site (Ito and 
Ho 1994; Kalueff 2007; Maksay and van Rijn 
1993). We found that RDX, a cyclical nitra-
mine, binds to the GABAA receptor convul-
sant site but does not bind to any of the other 
neuro  transmitter or neuro  modulator recep-
tors we studied. RDX displaced TBPS, a non-
competitive (for GABA) ionophore blocker, 
which acts at the picro  toxin convulsant site 
(Ito and Ho 1994; Kalueff 2007; Maksay and 
van Rijn 1993). RDX also displaced TBOB, 
which appears to bind at the same site as 
TBPS, and with kinetics similar to those of 
TBPS (Maksay and van Rijn 1993). Thus, 
RDX binds inside the chloride ionophore at 
a convulsant site overlapping with TBPS. The 
potency of RDX at the GABAA convulsant site 
(Ki of 21.1 µM) is similar to pentylene  tetrazol, 
a convulsant commonly used in animal models 
of seizure and epilepsy that is also known to 
bind at the picrotoxin convulsant site (Coulter 
et al. 1990).
We tested the functional implications of 
RDX binding to the picrotoxin convulsant site 
in the amygdala, a limbic structure that plays 
a central role in the generation and propa-
gation of seizures (Aroniadou-Anderjaska 
et al. 2008) and is a primary target for neuro-
toxins, including warfare neuro  toxins such as 
nerve agents (Apland et al. 2009; Aroniadou-
Anderjaska et al. 2009; Shih et al. 2003). 
We found that RDX significantly reduced 
the frequency and amplitude of action-
  potential–dependent sIPSCs in the BLA, the 
amygdala nucleus that plays the primary role 
Figure 5. RDX reduced GABA-evoked currents in the BLA. Whole-cell recordings from principal neurons in the BLA were obtained in the presence of CNQX, 
AP-5, and SCH50911. (A) RDX (40 µM) reduced the outward postsynaptic current elicited by 500-msec pressure application of 200 µM GABA onto a pyramidal BLA 
neuron (Vh = +40 mV). (B) RDX (40 µM) reduced the inward postsynaptic current elicited by 500-msec pressure application of 200 µM GABA onto a pyramidal BLA 
neuron (Vh = –70 mV). In both A and B, each current trace is the average of four current recordings, and the black bar indicates the period of GABA application. 
After recording control current traces, RDX was applied to the bath; 4 min later, several GABA-evoked currents were recorded. Current amplitudes recovered 
partially after the wash  out of RDX. (C) Group data (mean ± SE; absolute current amplitude from both Vhold +40 mV and Vhold –70 mV experiments; n = 6) showing 
the effect of RDX on the amplitude of GABA-evoked currents. 
#p < 0.05. 
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in seizure generation (Aroniadou-Anderjaska 
et al. 2007, 2008; Mohapel et al. 1996; White 
and Price 1993). Consistent with the results 
from the binding studies described here, RDX 
reduced sIPSCs by a post  synaptic action on 
GABAA receptors. This is supported by the 
significant reduction of the post  synaptic cur-
rents evoked by locally applied GABA in the 
presence of RDX. The prolonged, seizure-like 
neuronal discharges recorded in the BLA in 
the presence of RDX were probably a result of 
the reduced inhibitory tone (reduced sIPSCs) 
throughout the BLA network because of the 
blockade of the GABAA channels by RDX. In 
a recent study in the northern bobwhite quail, 
Gust et al. (2009) found many molecu  lar 
alterations in the brain after terminal RDX-
induced seizures, including alterations in the 
expression of genes involved in the regulation 
of neuronal excitability. 
RDX did not affect the activity of brain 
or peripheral blood AChE. The reported 
increased salivation and lacrimation after pro-
longed, low-dose RDX intoxication (Burdette 
et al. 1988; Crouse et al. 2006; Schneider et al. 
1977) may be mediated by the effect of RDX 
at the GABAA receptor, similar to the effects of 
type II pyrethroid esters (Ecobichon 2001).
Conclusions
In the present study, we found that RDX 
induces seizures by binding to the picrotoxin 
convulsant site of the GABAA ionophore, 
thereby reducing GABAergic inhibitory trans-
mission. We studied the effect of RDX on 
GABAergic synaptic transmission in the baso-
lateral nucleus of the amygdala. Along with 
previous studies (Burdette et al. 1988; Levine 
et al. 1990; Macphail et al. 1985), the present 
study suggests that the amygdala is involved 
in the seizuro  genic effects of RDX; however, 
other brain regions may also be significantly 
involved. In addition, although we performed 
RDX binding studies for a number of neuro-
transmitter and neuro  modulator receptors 
as well as sodium channels, the list certainly 
is not exhaustive; RDX might also bind to 
other channels that affect neuronal excitability, 
which we did not test in the present study. The 
mecha  nism of RDX seizure induction revealed 
in the present study in rats is probably similar 
in humans, because the binding charac  teris  tics 
of TBPS to the GABAA receptor are similar 
in rat and human brain (Atack et al. 2007; 
Cole et al. 1984). Knowing that RDX induces 
seizures by binding to the GABAA ionophore 
can guide treatment efforts in cases of RDX 
over  exposure and contribute to the develop-
ment of drugs that will prevent the onset of 
seizures without producing sedation or other 
undesirable effects. Furthermore, with other 
potential munitions in development by the 
military, knowledge of the molecular site and 
the mecha  nism of RDX action with respect 
to seizure induction can help prevent the 
develop  ment of explosives or other munitions 
that could pose similar health risks.
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